Ameritas Investment Partners, Inc. Allogene Therapeutics, Inc. Transaction History
Ameritas Investment Partners, Inc.
- $2.84 Billion
- Q2 2024
A detailed history of Ameritas Investment Partners, Inc. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 8,104 shares of ALLO stock, worth $22,691. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,104
Previous 8,104
-0.0%
Holding current value
$22,691
Previous $36,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ALLO
# of Institutions
176Shares Held
132MCall Options Held
94.3KPut Options Held
112K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$52.4 Million1.08% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$46 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$22.9 Million0.0% of portfolio
-
State Street Corp Boston, MA7.67MShares$21.5 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$19.3 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $403M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...